CVS - CVS Health Corporation

NYSE - NYSE Delayed Price. Currency in USD
73.68
+0.48 (+0.66%)
At close: 4:01PM EDT
Stock chart is not supported by your current browser
Previous Close73.20
Open73.04
Bid0.00 x 800
Ask0.00 x 800
Day's Range72.77 - 74.24
52 Week Range60.14 - 84.00
Volume7,145,938
Avg. Volume7,768,255
Market Cap74.907B
Beta0.88
PE Ratio (TTM)11.30
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.00 (2.93%)
Ex-Dividend Date2018-07-24
1y Target EstN/A
Trade prices are not sourced from all markets
  • CVS Health's PBM Selling Season Strong, Aetna Deal on Track
    Zacks4 days ago

    CVS Health's PBM Selling Season Strong, Aetna Deal on Track

    A solid 2019 PBM selling season is a significant positive for CVS Health's (CVS) growth. The company completes more than 70% of its client renewals, almost in line with the prior-year level.

  • InvestorPlace4 days ago

    Why Does Mark Cuban Own Netflix, Amazon Shares When He’s Worried About the Market?

    Billionaire entrepreneur and investor Mark Cuban appeared on CNBC recently and sounded a cautious tone about the stock market. In this column, I will explain why someone who is cautious about the stock market can be bullish about NFLX stock and AMZN stock. Cuban does own four dividend stocks.

  • Reuters5 days ago

    From blue lipstick to Facebook Live, home shopping networks refine their pitch

    HSN, once known as the Home Shopping Network, is getting an image makeover. A U.S. television network where shoppers can buy everything from electronics to kitchen gadgets, HSN is overhauling its lineup to offer more beauty products while adding streamed video content to win over shoppers without cable TV. A division of Qurate Retail Group, the network is facing growing competition from Amazon Inc. and Evine Live Inc for consumers like 24-year old Erin Bounds, who regard buying products through TV shows a relic of the past.

  • Olay spotlights fearless women in 'Face Anything' campaign
    American City Business Journals5 days ago

    Olay spotlights fearless women in 'Face Anything' campaign

    The ads feature women who have been called "too" something instead embracing their boldness.

  • Reuters5 days ago

    Express Scripts staking out million-dollar gene therapies

    Now it is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs. Express Scripts is in talks with biotechnology companies Biomarin Pharmaceutical Inc (BMRN.O), Spark Therapeutics Inc (ONCE.O) and Bluebird Bio Inc (BLUE.O) to have its specialty pharmaceutical business exclusively distribute their new haemophilia therapies when they are expected to become available in 2019 and 2020, Chief Medical Officer Steve Miller told Reuters in an interview.

  • Top Gainers in the Consumer Sector Last Week
    Market Realist6 days ago

    Top Gainers in the Consumer Sector Last Week

    CVS Health (CVS) released its second-quarter results on August 8 before the market opened. The company’s revenues for the quarter grew 2.2% YoY (year-over-year) to $46.7 billion and beat the estimate by 0.8%. CVS Health’s earnings increased 27.1% YoY to $1.6 per share and exceeded the forecast of $1.6 per share.

  • Consumer Sector Was Mediocre in the Week Ending August 10
    Market Realist6 days ago

    Consumer Sector Was Mediocre in the Week Ending August 10

    So far, 91% of the companies in the S&P 500 have reported their third-quarter earnings. Last week was mediocre for the market. The S&P 500 Index (SPY) fell 0.25% for the week ending August 10. Last week was average for most of the sectors in the index.

  • Moody's6 days ago

    Rite Aid Pass-Through Trust, Series 1999-1 -- Moody's Places the CTL Rating of Rite Aid Pass-Through Trust, Series 1999-1 On Review For Possible Downgrade

    The rating was placed on review for possible downgrade due to the Rite Aid Corporation ("Rite-Aid") senior unsecured rating being placed on review for possible downgrade by Moody's on August 9, 2018. Rite-Aid was placed on review for possible downgrade due to Rite-Aid's announcement that it has terminated its merger agreement with Albertsons Companies, Inc. The merger termination leaves Rite-Aid in a weaker position as it lacks the scale or the balance sheet to compete in the changing pharmacy landscape with much larger and well capitalized competitors like CVS Health and Walgreens Boots Alliance, Inc. The ratings of Credit Tenant Lease (CTL) deals are primarily based on the senior unsecured debt rating (or the corporate family rating) of the tenants leasing the real estate collateral supporting the bonds.

  • An economist’s change of heart: It’s time to regulate the prescription-drug middlemen
    MarketWatch7 days ago

    An economist’s change of heart: It’s time to regulate the prescription-drug middlemen

    Pharmacy-benefit managers may drive hard bargains with drug manufacturers, but they keep finding ways to boost their bottom line at the expense of employers and patients.

  • Is Rite Aid Corporation a Buy?
    Motley Fool8 days ago

    Is Rite Aid Corporation a Buy?

    Another merger falls apart for Rite Aid. But could better days be ahead?

  • CVS Health (CVS) Q2 2018 Earnings Conference Call Transcript
    Motley Fool10 days ago

    CVS Health (CVS) Q2 2018 Earnings Conference Call Transcript

    CVS earnings call for the period ending June 30, 2018.

  • Top Research Reports with Q2 Earnings Analysis: Merck, CVS Health, CME Group & More
    Zacks10 days ago

    Top Research Reports with Q2 Earnings Analysis: Merck, CVS Health, CME Group & More

    Top Research Reports with Q2 Earnings Analysis: Merck, CVS Health, CME Group & More

  • CVS nasal spray recalled due to contamination fears
    CBS MoneyWatch10 days ago

    CVS nasal spray recalled due to contamination fears

    CVS Health 12 Hour Sinus Relief Nasal Mist, a clear, colorless liquid, is a nasal decongestant

  • Strong Q2 2018 Results Cushion CVS Health’s Falling Share Price
    Market Realist10 days ago

    Strong Q2 2018 Results Cushion CVS Health’s Falling Share Price

    CVS Health’s (CVS) better-than-expected second-quarter results managed to please investors. The company’s share price soared 6% during the day on August 8 before finally settling at $68.17, 4.2% higher than the previous day’s close.

  • Is Walgreens Stock an Attractive Bet?
    Market Realist10 days ago

    Is Walgreens Stock an Attractive Bet?

    As discussed in the previous section, six analysts have downgraded Walgreens Boots Alliance (WBA) since Amazon’s (AMZN) acquisition of PillPack in late June. As a result, Walgreens’s overall ratings have come down drastically. The company, which was rated 2.3 before the acquisition on June 28, is now ranked as a 2.7. Ratings are on a scale where one is a “strong buy,” and five is a “strong sell.”

  • Moody's10 days ago

    Rite Aid Corporation -- Moody's places Rite Aid's rating on review for downgrade following termination of merger with Albertsons

    Moody's Investors Service ("Moody's") today placed the ratings of Rite Aid Corporation (Rite-Aid) on review for downgrade including its Corporate Family Rating of B2 and its Probability of Default Rating of B2-PD. The review for downgrade is prompted by Rite-Aid's announcement that it has terminated its merger agreement with Albertsons Companies, Inc.

  • Strong Retail Margins Boost CVS Health’s Q2 2018 Operating Profit
    Market Realist11 days ago

    Strong Retail Margins Boost CVS Health’s Q2 2018 Operating Profit

    CVS Health (CVS) once again cruised ahead of bottom line expectations when it reported its second-quarter results yesterday morning. Its adjusted EPS rose 27.1% YoY (year-over-year) to $1.69, $0.08 more than the Thomson Reuters I/B/E/S estimate. This was the tenth consecutive earnings beat for the company.

  • TheStreet.com11 days ago

    Rite Aid's Rotten Week: How Will It Now Compete Against Walgreens, CVS?

    Rite Aid had a horrid week. The stock has been pummeled by a spate of bad news, raising questions about how Rite Aid will continue to stack up against its competitors on pricing, footprint and innovation edge. The slide thus far was punctuated by a collapse of a merger agreement with Albertsons Cos. grocery chain, sinking the shares over 9% on Thursday to $1.58 per share.

  • Strength in Retail Sales Drives CVS Health’s Q2 2018 Top Line
    Market Realist11 days ago

    Strength in Retail Sales Drives CVS Health’s Q2 2018 Top Line

    CVS Health (CVS) posted better-than-expected quarterly sales when it reported its second-quarter results on August 8. Its top line improved 2.2% YoY (year-over-year) to $46.7 billion.

  • Barrons.com11 days ago

    Another Rite Aid Merger Collapsed. There's No Cure in Sight

    Some Rite Aid stockholders were apparently unwilling to approve the pharmacy chain's merger with grocer Albertsons in a vote scheduled Thursday, so on Wednesday night, Rite Aid and Albertsons called off the merger. Rite Aid's balky shareholders may rue their opposition to the deal. In heavy trading, Rite Aid (RAD) stock was down about 10% early Thursday afternoon, to just $1.56 a share. Pharmacies are in the thick of the transformation of the health care economy.  CVS Health (CVS) wants to merge with insurer Aetna (AET), while benefits manager Express Scripts Holdings (ESRX) aims to join insurer  Cigna (CI).

  • Rite Aid Stock Plunges on Collapse of Albertsons Merger
    InvestorPlace11 days ago

    Rite Aid Stock Plunges on Collapse of Albertsons Merger

    Rite Aid notes that the reason it is no longer moving forward with the merger is due to the views of its shareholders. Rite Aid also points out that the agreement between it and Albertsons doesn’t require a payment from either company for the cancellation of the merger agreement. “We will continue building momentum for key areas of our business like our innovative Wellness store format, highly successful customer loyalty program and expanded pharmacy service offerings, as we also enhance our omni-channel and own brand offerings to strengthen our competitive position and create long-term value for stockholders,” Rite Aid Chairman and CEO John Standley said in a statement.

  • CVS Health Beats on Q2 2018 Top and Bottom Lines
    Market Realist11 days ago

    CVS Health Beats on Q2 2018 Top and Bottom Lines

    CVS Health (CVS) reported its second-quarter earnings results on August 8. The pharmacy giant reported better-than-expected top and bottom line results during the quarter.

  • Walgreens’s Stock Performance This Year: The Ups and Downs
    Market Realist11 days ago

    Walgreens’s Stock Performance This Year: The Ups and Downs

    Walgreens Boots Alliance (WBA) stock has been in the red almost throughout the whole year so far. Interestingly, the pharmacy giant’s stock performance hasn’t been driven by its own financial performance, but by Amazon’s expansion plans in the pharma space. Walgreens has reported quarterly results for the first three fiscal quarters of 2018 this year.

  • Zacks.com highlights: CVS Health, Meritage Homes, Big Lots, Rayonier Advanced Materials, ON Semiconductor and PCM
    Zacks11 days ago

    Zacks.com highlights: CVS Health, Meritage Homes, Big Lots, Rayonier Advanced Materials, ON Semiconductor and PCM

    Zacks.com highlights: CVS Health, Meritage Homes, Big Lots, Rayonier Advanced Materials, ON Semiconductor and PCM

  • The Wall Street Journal11 days ago

    [$$] CVS Chief: Don’t Blame Us for Higher Drug Prices

    CVS Health Corp. Chief Executive Larry Merlo said Wednesday that industry middlemen aren’t responsible for increasing U.S. drug prices, noting that prices are rising faster for medicines with smaller manufacturer rebates. CVS owns Caremark, one of the biggest pharmacy-benefit managers, which process prescriptions for insurers or companies that pay for medicines and use their size to negotiate with drugmakers and pharmacies. Mr. Merlo said CVS expects 3%, or about $300 million, of its 2018 earnings to come from rebates it pockets.